Table 1.
Baseline Clinical Characteristics
| Patient Characteristics (n = 75) | All Patients |
TMB Low |
TMB High |
p Value |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | ||
| Age (years), median (range) | 66 (42–87) | 66 (43–85) | 65 (42–87) | 0.7739 |
| Gender | ||||
| Male | 37 (49) | 17 (45) | 20 (54) | 0.4916 |
| Female | 38 (51) | 21 (55) | 17 (46) | |
| Histology | ||||
| Non-squamous | 59 (79) | 31 (82) | 28 (76) | 0.5829 |
| Squamous | 16 (21) | 7 (18) | 9 (24) | |
| Smoking status | ||||
| Current/former | 60 (80) | 24 (63) | 36 (97) | 0.0003 |
| Never | 15 (20) | 14 (37) | 1 (3) | |
| Stage | ||||
| IIIB | 9 (12) | 6 (16) | 3 (8) | 0.4799 |
| IV | 66 (88) | 32 (84) | 34 (92) | |
| Performance status | ||||
| ECOG 0 | 30 (40) | 16 (42) | 14 (38) | 0.8147 |
| ECOG 1 | 45 (60) | 22 (58) | 23 (62) | |
| PD-L1 expression | ||||
| 0% | 25 (33) | 13 (34) | 12 (32) | 0.8037a |
| ≥1% | 45 (60) | 21 (55) | 24 (65) | |
| Unknown | 5 (7) | 4 (11) | 1 (3) | |
| Best overall response | ||||
| Complete/partial response | 24 (32) | 5 (13) | 19 (51) | 0.0018 |
| Stable disease | 27 (36) | 17 (45) | 10 (27) | |
| Progression/not evaluable | 24 (32) | 16 (42) | 8 (22) | |
| Clinical benefit | ||||
| Durable clinical benefit (DCB) | 37 (49) | 13 (34) | 24 (65) | 0.0111 |
| No durable benefit (NDB) | 38 (51) | 25 (66) | 13 (35) | |